Patient characteristics
| First postprogression treatment . | CPI (n = 70) . | BV (n = 157) . | No CPI/BV∗ (n = 117) . | P value . |
|---|---|---|---|---|
| Age | .971 | |||
| Median (IQR) | 35 (26-47) | 33 (27-48) | 34 (26-44) | |
| Sex, n (%) | .279 | |||
| F | 31 (42.9%) | 80 (51.0%) | 55 (47.0%) | |
| M | 39 (55.7%) | 77 (49.0%) | 62 (53.0%) | |
| EN disease | 31 (44.3%) | 51 (32.5%) | 50 (42.7%) | .342 |
| B symptoms | 35 (50.0%) | 56 (37.3%) | 55 (47.8%) | .111 |
| PRD | 16 (22.9%) | 42 (26.8%) | 30 (25.6%) | .1 |
| Early relapse | 28 (40.0%) | 54 (34.4%) | 57 (48.7%) | .1 |
| >1 line of salvage | 25 (35.7%) | 42 (26.8%) | 48 (41.0%) | .042 |
| Pre-ASCT positive PET | 30 (42.9%) | 81 (51.9%) | 70 (61.4%) | .045 |
| TTP | <.001 | |||
| <6 | 22 (31.4%) | 76 (48.4%) | 76 (65.0%) | |
| >6 | 48 (68.6%) | 81 (51.6%) | 41 (35.0%) |
| First postprogression treatment . | CPI (n = 70) . | BV (n = 157) . | No CPI/BV∗ (n = 117) . | P value . |
|---|---|---|---|---|
| Age | .971 | |||
| Median (IQR) | 35 (26-47) | 33 (27-48) | 34 (26-44) | |
| Sex, n (%) | .279 | |||
| F | 31 (42.9%) | 80 (51.0%) | 55 (47.0%) | |
| M | 39 (55.7%) | 77 (49.0%) | 62 (53.0%) | |
| EN disease | 31 (44.3%) | 51 (32.5%) | 50 (42.7%) | .342 |
| B symptoms | 35 (50.0%) | 56 (37.3%) | 55 (47.8%) | .111 |
| PRD | 16 (22.9%) | 42 (26.8%) | 30 (25.6%) | .1 |
| Early relapse | 28 (40.0%) | 54 (34.4%) | 57 (48.7%) | .1 |
| >1 line of salvage | 25 (35.7%) | 42 (26.8%) | 48 (41.0%) | .042 |
| Pre-ASCT positive PET | 30 (42.9%) | 81 (51.9%) | 70 (61.4%) | .045 |
| TTP | <.001 | |||
| <6 | 22 (31.4%) | 76 (48.4%) | 76 (65.0%) | |
| >6 | 48 (68.6%) | 81 (51.6%) | 41 (35.0%) |
EN, extranodal; IQR, interquartile range; n, number; PRD, primary refractory disease.
No CPI/BV group includes patients who did not receive BV or CPI as first salvage therapy.